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1.0 Background
Alzheimer’s disease (AD) presents a unique challenge. It’s the only top ten cause of 
disability that doesn’t have a therapy to slow its progression[1]. Several large clinical trials 
are actively studying individuals in order to discover potential therapies by 2025[1]. The 
success of these trials, however, depends upon individuals being willing to undergo gene and 
biomarker testing and learn the related risk of AD dementia. AD stigma presents an obstacle 
to them doing this[1,2].
Stigma of AD dementia can take the form of one or more of a collection of beliefs, 
behaviors, and attitudes. The assumptions made about AD and people with the disease often 
reflect those that confirm stereotypes about symptoms or functional abilities. These 
stereotypes often depict the later stages of disease when a person is most impaired and fully 
dependent upon others for care[3–6]. As a result of these negative expectations, stigma can 
discourage a person from seeking diagnosis, educating themselves about the disease, and 
participating in research[2,7–9]. It can also lead people to react poorly such as patronizing, 
isolating, and discriminating against a person with the disease[10–12].
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Stigma of AD dementia can differ based upon one’s personal characteristics and beliefs 
about a disease. As compared to no diagnosis, a diagnosis of AD dementia can mitigate 
against some forms of stigma, such as harsh judgements about a person’s poor hygiene or 
aesthetics[13]. But its prognosis – that symptoms are expected to worsen over time— can 
exacerbate discrimination, pity, and social distance. Belief that AD dementia is a mental 
illness exacerbates how individuals judge the severity of a person’s symptoms[14]. Other 
personal characteristics of a person, like age and gender, can also affect how they judge or 
react to someone with AD dementia[14].
Understanding the composition of beliefs, attitudes, and expectations about AD dementia 
held by the general public could help inform specific strategies to mitigate stigma and its 
consequences. If, for example, members of the general public don’t only worry that a person 
with AD dementia faces discrimination[14] but also worry specifically that a confirmatory 
genetic test for AD could make a person vulnerable to being discriminated against by health 
insurance purveyors, this knowledge would be valuable for informing how to direct public 
education about certain policies, like The Genetic Information Nondiscrimination Act of 
2008 (GINA)[15] which offers protections against gene based healthcare insurance 
discrimination. Alternatively, such information could help identify gaps in current policy 
protections, whereby concerns among the public are common but policy protections are 
lacking or insufficient. Together, this information could be useful for understanding factors 
that deter individuals from seeking care or enrolling in AD research.
The purpose of this study was to understand what features or attributes are most commonly 
paired with AD dementia by the public. Based on prior studies,[13,14] we hypothesized that 
concerns about discrimination and the propensity to over-attribute the severity to symptoms 
would be among the most prevalent. Among those most common, we sought to determine 
whether their prevalence differed based on characteristics of population subgroups. We 
expected that older respondents would be more likely to expect a person with AD would 
encounter employment discrimination and that African American respondents would be less 
likely than White respondents to expect a person with AD would be excluded from medical 
decision-making. Understanding which attributes are most often associated with AD 
dementia by the public may help identify the most overt and wide-reaching concerns related 
to the disease, which may help inform interventional programs and policy changes to reduce 
AD stigma.
2.0 Methods
2.1 Study Design
This is a secondary analysis of how a random sample of adults from the general U.S. public 
reacted to a fictional description of a person with mild stage AD dementia. The data 
analyzed in the present study are a subset of those used in studies [13] and [14].
2.2 Data Source
Data were obtained from an experimental study that examined whether the cause and 
prognosis of mild dementia were related to how adults in the general population judged a 
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person with mild AD dementia. The study asked respondents to read a vignette and then 
complete a survey. Respondents were recruited September 5th through 13th 2013 by an 
online panel provider. The demographic profiles of online panels have been shown to be 
representative of the U.S. general population[16].
The survey was distributed to a random sample likely to be adults in the U.S. who were able 
to provide informed consent and read English. The survey completion rate was 58%. 
Respondents were asked to provide standard demographic information. The collection of 
race and ethnicity information was informed by the Census Alternative Questionnaire 
Experiment[17]. Respondents were asked to self-identify by race or ethnicity or by multiple 
races.
The original study used a 3×3 factorial design whereby consenting adults (N=1,025) were 
assigned to 1 of 9 conditions using unrestricted simple randomization[18]. In the present 
study, we analyzed data from 317 of those respondents randomized to 3 of the 9 conditions. 
All of these respondents were told the cause of the mild stage dementia was AD. The three 
conditions differed based on whether they were told the person’s condition would 1) worsen, 
2) improve, or 3) remain unchanged. A fuller description of the design and randomization is 
available elsewhere[14].
2.3 Vignette Design
The original study used vignettes to examine how diagnostic label and prognosis contributed 
to attitudes, emotions, and expectations expressed by the general public. The study was 
described to participants as being about “health beliefs” and did not mention AD during 
recruitment or consent.
The vignette described a man suffering from impairments typical of the mild stage of AD 
dementia. The symptoms described were consistent with observable impairments in six 
domains of the Clinical Dementia Rating scale[19]: memory, orientation, judgment and 
problem solving, community affairs, home and hobbies, and personal care.
To personalize the vignette, the character was given a name, Mr. Andrews, and referred to as 
“he.” Pilot versions of the survey included male and female versions of the vignette, but 
restrictions in sample size required reducing the number of vignettes. Interest in being 
consistent with previous research in which vignettes relied on male characters[11], favored 
retaining the male version of the vignette. Studies of AD dementia that have experimentally 
varied the gender of non-familial vignette characters have not found appreciable differences 
in reactions among the general public[20,21]. No other demographic characteristics of the 
vignette character were given.
After reading the vignette, respondents were given a comprehension test to confirm that they 
accurately understood the salient details. They had two opportunities to answer correctly. 
Those who failed on the second attempt were excluded (Appendix Figure A). After this 
exclusion, the final sample in the present study included data from 317 respondents.
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2.4 Study Measures
A modified version of the Family Stigma in Alzheimer’s Disease Scale (FS-ADS[22]) was 
used to assess the beliefs, feelings, and expectations of respondents. Some items on the 
original instrument were adapted for understandability and relevance in the context of the 
current study (See Supplemental materials in [13]). The modified FS-ADS asked 
respondents how likely they believed the person (described in the vignette) would be to have 
his healthcare insurance limited due to documentation in his medical record, due to a result 
from a brain scan, or due to a result from a genetic test. Respondents were also asked the 
extent to which they expected the person would be discriminated against by employers, 
excluded from voting or medical decision-making, or exhibit certain symptoms like not 
remembering recent events, failing at simple tasks, or suffering incontinence. In addition, 
respondents were asked about their expectations for the person’s aesthetics – like whether 
they expected the person to have poor hygiene or neglect self-care – and the extent to which 
they expected people would be disgusted or repulsed by the person. Respondents were asked 
the extent to which they expected others to feel concern, compassion, sadness, pity, or to 
behave in ways that ignored, isolated, or helped the person. Responses were given on a scale 
from 1 to 5 with higher scores indicating stronger endorsement.
A shortened Alzheimer's Disease Knowledge Scale (ADKS[23]) was used to evaluate 
general knowledge of Alzheimer’s disease. The abbreviated instrument omitted eight items 
on the original assessment because they could have been answered using information in the 
vignette[13]. Respondents were also asked to rate the degree that they felt the person’s 
condition (i.e., Alzheimer’s disease) was a mental illness from “not at all” (1) to “a very 
great extent” (5). A fuller description of the study’s methods is available elsewhere[13].
2.5 Statistical Analysis
Responses of 4 and 5 on the FS-ADS were considered a positive result in the present study. 
This cut point was consistent with the 50th percentile or above on all items and the 75th 
percentile or above on 21 of 44 items. Adjusted generalized linear models (GLMs) with a 
log link were used to estimate the percentage of the respondents who strongly endorsed each 
item on the modified FS-ADS. These models adjusted for study prognostic condition (i.e., 
static, improve, worsen). In order to mitigate family-wise errors of the first kind, a limited 
number of items were carried forward for further analysis[24]: those endorsed by 60% or 
more of respondents in the condition where the person’s prognosis was expected to worsen.
In separate bivariate analyses, we used GLMs with a log link to estimate the percentages of 
respondents strongly endorsing each outcome when they were told the person’s condition 
would worsen, improve, or remain unchanged over time. In these analyses, estimates with 
95% confidence intervals that do not overlap are statistically significant at P<0.05 (Table 3). 
To build a multivariate model, we used forward step-wise selection in multivariable GLMs 
to construct statistical models that adjusted for interrelationships among respondent 
characteristics (Alpha-to-Keep≤0.20). Candidate covariates were all assessed demographic 
characteristics, general knowledge about AD, and strength of belief that this disease was a 
mental illness. We then entered the retained covariates together into a multivariate analysis 
that statistically adjusted for variance shared among the outcomes. We report differences in 
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percentages of respondent endorsement for each outcome and their respective 95% 
confidence intervals. In these analyses, estimates with 95% confidence intervals that do not 
include zero are statistically different from zero (P<0.05; Table 4). The multivariable 
analyses have at least 89% power to detect a difference of 8% or more.
Respondents’ caregiver status was excluded from analysis as small group size prohibited 
comparisons (n = 19) and its inclusion as a covariate did not substantively alter the main 
results[25]. All independent variables were screened for multicollinearity (correlation 
coefficient r >0.7). In analyses that adjusted for multiple comparisons, all independent 
variables were screened for interactions with study prognostic category (p>5.0). All 
statistical tests were two-sided. P values ≤0.05 were considered statistically significant. All 
statistical analyses were performed using Stata 14 (College Station, TX).
3.0 Results
3.1 Respondent Characteristics
In a sample of 317 adults in the general public, respondents’ median age was 49 years (IQR 
29), about half (49%) were female, most (80%) self-identified as White (non-Latino), and 
over half (65%) had less than a 4-year college degree. (Table 1)
In analyses that adjusted statistically for study prognostic condition, about three-quarters of 
respondents expected that a person with mild stage AD dementia would not remember most 
recent events (73.8%, 95%CI 65.8 to 82.7). In adjusted analyses, over half of respondents 
expected a person with AD dementia would be discriminated against by employers (55.3%, 
95%CI 47.0 to 65.2) and would be excluded from medical decision-making (55.3%, 95%CI 
46.9 to 65.4; Table 2). Similarly, high percentages expected the person would have his 
healthcare insurance limited due to data in the medical record (46.6%, 95%CI 38.0 to 57.2) 
or have his healthcare insurance limited due to a brain imaging result (45.6%, 95%CI 37.0 to 
56.3).
3.2 Effects of Alzheimer’s Disease Prognosis
When explicitly informed that the condition of the person with AD dementia would worsen 
over time, most respondents expected the person would encounter employment 
discrimination (78.4%, 95%CI 70.4 to 86.5; Table 3). This percentage was substantially 
higher than when respondents were told that the person’s condition either would improve 
(63.4%, 95%CI 54.4 to 72.4) or would remain unchanged (55.3%, 95%CI 45.7 to 65.0).
When informed that the condition of the person with AD dementia would worsen over time, 
most respondents expected the person would have his healthcare insurance limited due to 
data in the medical record (65.7%, 95%CI 56.4 to 75.0) or due to a brain imaging result 
(62.7%, 95%CI 53.3 to 72.2). Both estimates were substantially higher than when 
respondents were told the person’s condition would improve or remain unchanged over time, 
46.6% (95%CI 36.9 to 56.3) and 45.6% (95%CI, 35.9 to 55.3) respectively.
About three-quarters of those told the condition of the person with AD dementia would 
worsen over time expected that the person would be excluded from medical decision-making 
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(73.5%, 95%CI 64.9 to 82.2). This percentage was about 33% higher than that for 
respondents told the person’s condition would improve over time (55.3%, 95%CI 45.7 to 
65.0). No statistically discernable difference was observed between respondents told the 
person’s condition would worsen and those told the person’s condition would remain 
unchanged (p>0.05).
3.3 Effects of personal characteristics, knowledge about Alzheimer’s disease dementia, 
and belief that Alzheimer’s disease is a mental illness
In a multivariate analysis, African American respondents were 20.6% (95%CI −40.6 to 
−0.6) less likely than White respondents to expect the person with AD dementia would 
encounter employment discrimination (Table 4). They were also less likely than White 
respondents to expect the person would have his healthcare insurance limited due to 
information in the medical record (−30.8%, 95%CI −51.8 to −9.9) or have his healthcare 
insurance limited due to a brain imaging result (−33.2%, 95%CI −54.3 to −12.1). In 
addition, they were 26.4% (95%CI −46.8 to −5.9) less likely than White respondents to 
expect the person would be excluded from medical decision-making.
Respondents age 50 and older were 17.4% (95%CI 6.6 to 28.1) more likely than younger 
adults to expect that the person with AD dementia would encounter employment 
discrimination. They were also more likely than those under age 50 to expect the person 
with AD dementia would have his healthcare insurance limited due to data in the medical 
record (13.7%, 95%CI 2.5 to 25.0) and to expect that he would not remember most recent 
events (11.5%, 95%CI 1.5 to 21.5).
Compared to those with weaker beliefs, respondents believing strongly that AD was a 
mental illness were more likely to expect a person with mild stage AD dementia would not 
remember most recent events (17.6%, 95%CI 7.5 to 27.7). They were also more likely to 
expect that the person would have his healthcare insurance limited due to a brain imaging 
result (17.4%, 95%CI 5.9 to 28.9).
4.0 Discussion
Analyses of a sample of 317 adults in the U.S. general population showed that the most 
common features attributed to a person with mild stage AD dementia were expecting the 
person would not remember most recent events (73.8%), would be discriminated against by 
employers (55.3%), and would be excluded from medical decision-making (55.3%). The 
least common attributes included expecting the person would be unkempt (11.7%), neglect 
self-care (6.8%), and have a bad odor (5.8%). These findings were consistent with our 
earlier study that found the diagnosis of AD dementia mitigates against negative judgments 
about a person’s aesthetic characteristics[13].
We found that almost half of respondents expected that, as a result of having an AD 
diagnosis, a person would have his healthcare insurance limited – because of data in the 
medical record (46.6%) or due to a brain imaging result (45.6%) or due to a genetic test 
result (44.7%). Our findings have implications for the success of the national Alzheimer’s 
plan’s goal of developing an effective therapy by 2025[1,2]. To achieve the ambitious goal, 
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individuals with mild or even no symptoms of AD dementia are currently being asked to 
enroll in prevention trials. These candidates are being identified and enrolled into prevention 
trials based on results of gene and biomarker testing that places them at elevated risk for 
developing the disease. Our findings suggest, however, that many people expect that gene 
and biomarker testing could result in healthcare insurance capitations. These expectations 
may affect a person’s willingness to learn AD gene and biomarker test results. This could 
substantially impede the success of prevention trials, which are dependent, for purposes of 
recruitment and the underlying science, on persons undergoing gene and biomarker testing 
and learning those results.
Educating the public about The Genetic Information Nondiscrimination Act of 2008 (GINA) 
[15], which offers protections against gene based healthcare insurance discrimination, may 
help address some of the public’s concerns. However, our findings suggest the public’s 
concerns also include issues unaddressed by GINA [26,27]. For example, while GINA offers 
protections for genetic test results, it does not extend to all types of testing, like brain 
imaging results[28]. Moreover, it does not offer protections for long-term care insurance, 
which is often a key factor for persons undergoing AD gene and biomarker testing[29,30].
Reducing public stigma of AD is important for facilitating the success of Alzheimer’s 
prevention research[1,2]. Reciprocally, research advances may help to mitigate AD stigma. 
In randomized comparisons, we found that when told the person’s prognosis would improve 
over time 24% to 41% fewer respondents expected that the person would encounter 
discrimination or exclusion than when told the person’s prognosis would worsen (Table 3). 
Thus, advances in therapies that improve the prognosis of AD could help reduce stigma.
Current efforts to discover therapies for AD contrast that of “improving” impaired 
functioning. These innovations focus on discovering interventions – behavioral and 
pharmaceutical – that interrupt the underlying neuropathophysiology in persons with no or 
mild symptoms[31]. In turn, this would slow or prevent cognitive and physical declines. In 
our study, with one exception, the fact that the person’s condition would remain unchanged 
showed no differences compared to the current status quo, whereby the person’s condition 
worsened over time. Our findings suggest that how advances in the science of AD therapies 
are communicated— as offering improved longevity vs. retaining functioning or preventing 
declines— could radically affect the social and psychological experience of the disease. 
Studies are needed to understand how advances in diagnosis, testing, and treatment may shift 
AD stigma and to help position these advances as opportunities to reduce AD stigma.
We assessed whether respondents reacted differently to a person with AD dementia based on 
whether they self-identified as White, African American, or another race. Given that as a 
social group African Americans do not hold the majority’s social power, which is essential 
for being able to create stigma [9,32], and that they have a higher probability of direct 
contact with persons with AD dementia, which aids in mitigating stigma[33], we expected 
AD stigma would be less common among this group than White respondents. In a 
multivariate analysis, we found support for our hypothesis; African American respondents 
were less likely than White respondents to endorse all but one of the five attributions. Our 
findings provide pilot data that suggest further research in this area is warranted. 
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Understanding whether these findings are replicable with larger samples and, if so, how 
other factors like beliefs about prognosis, moderate them may help inform efforts to address 
the low participation of African Americans in AD research.
Our results are consistent with prior studies that have found members of the general public 
can react differently toward a person with AD dementia based on their ages [14,34]. In the 
current study, we found older age and stronger belief that AD dementia was a mental illness 
was related to how respondents reacted to the person with AD dementia. These findings 
suggest that, in addition to ensuring appropriate policy protections exist, it may be necessary 
to focus on distributing information about these policies within certain population 
subgroups.
A strength of this study is that the sample was drawn randomly from a large national panel. 
This type of panel has been found to be representative of the general population[16]. 
Moreover, respondents were randomized to the diagnosis and prognosis categories. Selection 
of a random sample and the random assignment of that sample to the study categories lends 
to the robustness of our findings. However, our sample of 317 is small to adequately reflect 
the rich diversity of the large U.S. general population. We acknowledge that our sample 
approximates the age, gender, and race composition of the general population. It also 
approximates the distribution for educational obtainment when adjusted for race-based 
disparities. But, particularly given its size, it cannot be fully representative of the nation. 
Further research with large random samples of the general population is needed to derive 
more precise estimates and to understand how stigma of Alzheimer’s disease may differ 
across divergent racial, ethnic, and socioeconomic groups[34–37]. In addition, our vignette 
described a specific patient with symptoms of mild stage dementia. Results to date from 
similar studies—particularly those that have experimentally varied the gender of the vignette 
character— have not found appreciable differences in reactions among the general public 
based gender of the vignette character. However, they have found evidence that suggests a 
person’s judgments about social roles, such as the vignette character’s identification as a 
“mother” or “father” can affect how that person judge’s someone with Alzheimer’s 
disease[20,21,38]. It’s an area that warrants further investigation. Moreover, although we did 
not find statistically significant differences based upon respondent gender, our analyses may 
not have had sufficient statistical power to detect these differences, which ranged from 1% to 
10.7% (Table 4).
Implications
Public education and policies are needed to address expectations of employment and 
insurance discrimination related to gene and biomarker risk data. In addition, it’s unlikely 
that advances in therapies will serendipitously reduce AD stigma. Studies are needed to 
understand how advances in diagnosis, testing, and treatment may shift AD stigma and to 
help position these advances as opportunities to reduce AD stigma.
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Appendix
Figure A. 
Study Flow through analysis in experiment examining stigmatizing attributions of dementia, 
Random Sample United States Adult Population 2013
Note. Respondents randomized to the Alzheimer ’s disease condition were included in the 
present analyses.
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Table A
Wording used in vignette to describe diagnosis and prognosis
Variable
Alzheimer’s disease (AD) Traumatic brain injury No disease label
Diagnosis The doctor does a complete 
examination of Mr. Andrews. This 
includes a medical history, memory 
tests, lab tests, and brain imaging. 
Based on this information, the 
doctor diagnoses Mr. Andrews with 
Alzheimer’s disease
The doctor does a complete 
examination of Mr. Andrews. This 
includes a medical history, memory 
tests, lab tests, and brain imaging. 
Based on this information, the 
doctor diagnoses Mr. Andrews with 
traumatic brain injury.
The doctor does a 
complete examination of 
Mr. Andrews. This 
includes a medical 
history, memory tests, lab 
tests, and brain imaging.
Symptoms improve with 
treatment
Symptoms are static with 
treatment
Symptoms worsen and 
there’s no treatment
Prognosis The doctor tells Mr. Andrews that 
treatment can improve his memory 
problems and functional difficulties.
The doctor tells Mr. Andrews that 
treatment can stop the worsening of 
Mr. Andrews’ memory problems 
and functional difficulties, but the 
treatment will not improve these 
problems.
The doctor tells Mr. 
Andrews that there are no 
treatments for Mr. 
Andrews’ memory 
problems and functional 
difficulties and that these 
problems will get worse.
Note. Respondents randomized to the conditions that conveyed the Alzheimer’s disease diagnosis were included in current 
analyses.
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Research in Context
1. Survey of random sample of general public: We surveyed a random sample of 
the general population to learn what beliefs, attitudes, and expectations are 
most often associated with AD dementia. This information may help inform 
strategies to mitigate stigma.
2. Interpretation of Main Results: People expected a person with AD would be 
discriminated against by employers, excluded from medical decision-making, 
and have his health insurance limited due to documentation in the medical 
record, a brain imaging result, or a genetic test result. Our results suggest that 
the general public may need education about existing policy protections. In 
cases where clearly no protections exist, our results support the need for 
policy development.
3. Future directions: Our findings call for research to understand how advances 
in diagnosis, testing, and treatment may shift AD stigma and to help position 
these advances as opportunities to reduce AD stigma.
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Table 1
Characteristics of Random Sample of Adult General Public (N=317)
Respondent
Characteristic
Alzheimer's
Disease
(N=317)
Age, median (IQR) 49 (29)
  65+ Years Old, % (n) 19.1 (61)
Females, % (n) 49.0 (156)
Race / Ethnicity, % (n)
  White, Non-Latino 80.4 (255)
  African American, Non-Latino 7.3 (23)
  Othera 12.3 (39)
Education, % (n)
  High School/GED or Less 23.7 (75)
  Some College or 2-year Degree 41.6 (132)
  4-Year College Degree or Beyond 34.7 (100)
Caregiver (Past or Present), % (n)b 6.0 (19)
Urban/Metro Setting,c % (n) 78.5 (249)
Mental Illness Rating,d median (IRQ) 3 (3)
Alzheimer's Disease Knowledge Scale (ADKS),e median (IQR) 15 (5)
Note. Column percentages may not total 100 due to rounding.
aCategory includes those who identified as Asian, Native American, multiple races, Hispanic or Latino only, other or did not respond (n=4).
b
Reported past or current primary caregiver of a person with Alzheimer’s disease.
c
Resides in urban rather than rural area based on Rural Urban Commuting Area (RUCA) classifications. Urban areas included RUCA classes 1 to 3 
and rural included classes 4 to 10.
d
Respondents were also asked to rate the degree the condition described in the vignette was a mental illness from “not at all” (1) to “a very great 
extent” (5).
eAbbreviated version. Maximum possible score = 22.
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Table 2
Adjusted Percentage of Respondents by Expected Features of Alzheimer's Disease (N=317)
Symptom Severity % (95%CI) Discrimination % (95%CI)
Doesn't Remember Recent Events 73.8 (65.8 to 82.7) Employers Discriminate 55.3 (47.0 to 65.2)
Repeats Self 32.0 (24.1 to 42.7) Excluded from Medical Decision-Making 55.3 (46.9 to 65.4)
Fails Simple Tasks 30.1 (22.4 to 40.4) Insurance Limited: Medical Record Data 46.6 (38.0 to 57.2)
Speech 16.5 (10.6 to 25.7) Insurance Limited: Brain Imaging Result 45.6 (37.0 to 56.3)
Speaks Nonsense 16.5 (10.4 to 26.3) Insurance Limited: Genetics 44.7 (36.0 to 55.4)
Disturbs Others 15.5 (9.6 to 25.2) Excluded from Voting 24.3 (16.8 to 35.1)
Incontinent 11.7 (6.3 to 21.4) Doctors Discriminate 20.4 (13.6 to 30.6)
Pity % (95%CI) Dangerousness % (95 %CI)
Sympathy 48.5 (39.8 to 59.2) To self 23.3 (16.4 to 33.1)
Pity 32.0 (23.9 to 43.0) To Others 7.3 (4.9 to 10.7)
Sadness 32.0 (23.9 to 42.9)
Sorrow 30.1 (22.2 to 40.7)
Antipathy % (95%CI) Social Distance % (95%CI)
Uneasy 23.3 (16.2 to 33.5) Hidden 27.2 (19.8 to 37.3)
Fear 20.4 (14.3 to 29.1) Social Contracts Limited 21.4 (14.3 to 31.9)
Embarrassed 11.7 (6.6 to 20.7) Avoided 20.4 (13.6 to 30.5)
Dread 11.7 (6.7 to 20.5) Kept Away from Others 19.4 (13.0 to 29.1)
Repulsed 10.7 (6.4 to 17.9) Ignored 19.4 (13.0 to 29)
Guilt 9.7 (4.1 to 7.1) Family Contacts Limited 11.7 (6.7 to 20.4)
Disgust 7.8 (3.9 to 15.6)
Disgrace 7.8 (4.0 to 15.2)
Aesthetics % (95%CI) Support % (95%CI)
Unkempt 11.7 (6.7 to 20.2) Concern 46.6 (37.9 to 57.3)
Filth 7.8 (4.1 to 14.6) Compassion 42.7 (34.1 to 53.5)
Neglected Self Care 6.8 (3.2 to 14.5) Willing to Assist 35.0 (26.9 to 45.5)
Looks Disgusting 5.8 (2.8 to 12.3) Support 33.0 (25.1 to 43.4)
Bad Odor 5.8 (2.4 to 14.1) Willing to Help 27.8 (20.2 to 38.3)
Note. 95%CI = 95% Confidence Interval. Results derived from Multivariable GLMs with log link that statistically controlled for prognostic study 
condition.
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Table 3
Percentage (95%CI) of Sample of General Public Endorsing Expected Features of Alzheimer's Disease by 
Study Prognostic Condition (N=317)
Improve
(n=103)
Static
(n=112)
Worsen
(n=102)
Doesn't Remember Recent Events 73.8 (65.8 to 82.7) 71.4 (63.0 to 79.9) 79.4 (71.5 to 87.3)
Employment Discrimination 63.4z (54.4 to 72.4) 55.3z (45.7 to 65.0) 78.4xy (70.4 to 86.5)
Exclusion from Medical Decision-Making 55.3z (45.7 to 65.0) 63.4 (54.4 to 72.4) 73.5x (64.9 to 82.2)
Insurance Discrimination due to Medical Record 46.6z (36.9 to 56.3) 51.8 (42.5 to 61.1) 65.7x (56.4 to 75.0)
Insurance Discrimination due to Brain Imaging Results 45.6z (35.9 to 55.3) 47.3 (38.0 to 56.6) 62.7x (53.3 to 72.2)
Note. 95%CI = 95% Confidence Interval. Results derived from Multivariable GLMs with log link.
Statistical significance denoted as:
xStatistically different than improve condition;
yStatistically different than static condition;
zStatistically different than worsen condition.
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